Hooda N, Suh M, Bylsma LC, Kelsh M. A systematic literature review of the association between dose reduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and survival in patients with HR-positive breast cancer (BC). Poster 1882eP, European Society for Medical Oncology (ESMO) Congress 2026, Madrid, Spain, October 23-27, 2026.
Abstract
This systematic review summarizes the evidence of the impact of dosage reductions on CDK4/6i on progression-free survival and overall survival in breast cancer patients in both clinical trial and real-world settings.